Molecular Endotypes of Chronic Idiopathic Urticaria
Part of paid clinical trials in Aurora, Colorado.
- Sponsor
- University of Colorado, Denver
- Study ID
- NCT04774315
- Phase
- PHASE4
- Status
- Active Not Recruiting
Conditions
- Chronic Urticaria, Idiopathic
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Accepted
Interventions
- Omalizumab — DRUGomalizumab 300mg SQ every 4 weeks as part of standard of care
Study Details
This study plans to learn more about why some people with Chronic Idiopathic Urticaria (CIU) respond to treatment with omalizumab (Xolair). It will test people before they receive treatment with omalizumab as part of standard of care, to see if there are differences in their blood and skin that can predict who responds to treatment.
Key Dates
- Start date
- Jan 1, 2022
- Status verified
- Aug 2024
- Primary completion
- Mar 31, 2025
- Completion
- Mar 31, 2025
Study Design
- Enrollment
- 15 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- DIAGNOSTIC
Arms
- Experimental: Omalizumab
Primary Outcome Measure
Responders [ Time Frame: Week 16 ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Colorado Anschutz | Aurora | Colorado | 80045 | - |
Find similar trials in Aurora, CO
By research site